Company intelligence / Profile preview
GoLiver Therapeutics
Nantes, Pays de la Loire, Francegolivertx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing injectable hepatocytes produced from human pluripotent stem cells to treat liver diseases as an alternative to liver transplantation. Recently awarded €1.6 million from France 2030 to progress their first biomedicine into clinical trials.
- Therapeutic areas
- Gastroenterology
- Modalities
- Cell therapyAdvanced Therapy Medicinal Products (ATMP)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on GoLiver Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GoLiver Therapeutics.